What stops bureaucrats from screwing you over is fear of oversight. If you have a valid complaint the fastest way to change a bureaucrat's attitude is ask to speak to a supervisor. Half the reason for the FDA letter was putting out a valid excuse for what they'd done up to that point.

The critical trial in Brazil, the data for cancer, the NASH 300mg data and hiring a CRO that can put a BLA together gives us that validity. It certainly seems that the FDA's attitude has changed towards Cytodyn for the better. With the evidence piling up in favor of Cytodyn the FDA doesn't want their supervisor (Congress) jumping into the fray. Especially after the tongue lashing they've gotten from the Covid-19 response and the approval of aduhelm.

So at this point we don't need any handholding from BP to speed up anything and potentially strip control of leronlimab away from Cytodyn.